Proprietary Insights – Stifel Discover delivers exclusive analysis and commentary from Stifel’s Chief Investment Officer, Chief Economist, Chief Washington Policy Strategist, equity research analysts, ...

In a report released on February 11, J. Bruce Chan from Stifel Nicolaus maintained a Buy rating on Hub Group (HUBG – Research Report), with a ...

MoneyLion operates a “content-as-a-service platform” called mFeed, and Stifel Discover is expected to deliver personalized ...

With deal activity expected to continue this year, deal advisors and analysts weigh in on how regulatory changes and private equity investment could play out in the sector.

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

In the eyes of Tesla shareholders, Elon Musk hardly needed another distraction. OpenAI could turn out to be a costly one.

Stifel analysts increased the price target for Confluent Inc (NASDAQ:CFLT), a data streaming platform, from $37.00 to $40.00, ...

Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dayforce Inc (NYSE:DAY – Free Report) by 31.8% during the 4th quarter, Holdings Channel reports. The firm owned 19,028 shares ...